Pasithea therapeutics announces financial and business results for the fourth quarter and full year 2021 and business update for 2022

-- cash balance of $52.9 million to fund operations well into 2024 ---- initiation of a drug development program in schizophrenia ---- initiation of a drug development program in multiple sclerosis ---- launched ketamine clinics in the u.k. and u.s. and expanded treatment options -- miami beach, fla., march 30, 2022 (globe newswire) -- pasithea therapeutics corp. (nasdaq: ktta) (“pasithea” or the “company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, is pleased to provide a business update and summary of key accomplishments since its initial public offering (“ipo”) in september 2021.
KTTA Ratings Summary
KTTA Quant Ranking